Tests BMS-986340 alone and combined in advanced solid tumors
Tests BMS-986340, alone or with other drugs, in adults with advanced solid tumors.
Plain-language title generated from the registry record
Registry title: A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Key facts
- Where
- Badalona, Barcelona, Madrid, Málaga, and Pamplona, SpainSee the 7 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic solid tumors who have already had standard treatments and whose disease has gotten worse.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Advanced or metastatic solid tumor with disease that can be measured on scans and has gotten worse on or after the latest treatment. ECOG performance status of 0 or 1.
- Earlier treatment
- People must have had standard treatments, including a PD-(L)1 inhibitor known to work for their tumor type, or cannot have them or cannot tolerate them. For some parts of the study (1C, 2C, 2D), people who had docetaxel for advanced or metastatic disease cannot join.
- Biomarker or test result
- A fresh tumor biopsy before treatment and another during treatment is required for biomarker testing. At least 1 tumor lesion must be reachable for biopsy.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Cancer of the brain or spinal cord, untreated spread to the brain, or spread to the membranes around the brain
- Another cancer needing treatment, or active within the last 2 years
- Active, known or suspected autoimmune disease
- Past organ or tissue transplant from a donor
Read by machine on 12 November 2026.
Where in Spain
- Institut Catalan d Oncologia (ICO) - BadalonaBadalona, SpainContact: Cinta Hierro Carbo, Site 0014Taking people
- Hospital Universitari Vall d'HebronBarcelona, SpainContact: Elena Garralda Cabanas, Site 0049Taking people
- Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid-CIOCCMadrid, SpainContact: Emiliano Calvo, Site 0011Taking people
- Hospital Universitario 12 de OctubreMadrid, SpainContact: Luis Paz-Ares Rodriguez, Site 0047Taking people
- Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJDMadrid, SpainContact: Victor Moreno Garcia, Site 0013Taking people
- Hospital Universitario Virgen de la VictoriaMálaga, SpainContact: Javier Garcia Corbacho, Site 0048Taking people
- Clinica Universidad de Navarra-oNCOLOGYPamplona, SpainContact: Ignacio Melero Bermejo, Site 0012Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT04895709
- Record updated
- 17 August 2026
- Original description
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.Read full original descriptionShow less
A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
Inclusion: Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis; Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable; Eastern Cooperative Oncology Group Performance Status of 0 or 1; Radiographically documented progressive disease on or after the most recent therapy; Received standard-of-care therapies, (except for Part 1C, 2C and 2D, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated; Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant.
Exclusion: Condition requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment; Prior organ or tissue allograft; Major surgery within 4 weeks of study drug administration; Primary central nervous system (CNS) malignancy; Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment; Active, known, or suspected autoimmune disease; Uncontrolled or significant cardiovascular disease; History of or with active interstitial lung disease or pulmonary fibrosis; Women who are pregnant or breastfeeding; Untreated CNS metastases; Leptomeningeal metastases; Other protocol-defined inclusion/exclusion criteria apply.